Guardant Health’s Blood-Draw Cancer Test Wins FDA Approval (1)

(Updates with Guardant share trading in first bullet, clarifies Roche’s test offerings in fifth bullet)

• Guardant Health Inc.’s cancer test, Guardant 360 won Food and Drug Administration Approval for use in all solid tumors, marking the agency’s first approval of a liquid biopsy cancer test. Shares rose as much as 6.2%.
• The nod should be the icing on the cake for Guardant’s diagnostic platform that profiles a cancer tumor to aim personalized treatments as well as clinical trials directly at patients
• “We have the ability in the U.S. to bend mortality curves, we just need to get those patients tested,” ...